Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZAI LAB

24.400
+1.6007.02%
Volume:13.01M
Turnover:316.26M
Market Cap:26.86B
PE:-12.10
High:24.850
Open:23.300
Low:23.200
Close:22.800
Loading ...

Zai Lab Ltd: Safety Profile of Tivdak Among China Subpopulation Was Manageable and Consistent With That Observed in Global Populatio

THOMSON REUTERS
·
15 Jan

Zai Lab Announces Positive Topline Results for Tivdak in the China Subpopulation of the Global Phase 3 Innovatv 301 Trial in Patients With Recurrent or Metastatic Cervical Cancer

THOMSON REUTERS
·
15 Jan

Zai Lab Ltd - to Submit Nda for Tivdak to Nmpa in Q1 2025

THOMSON REUTERS
·
15 Jan

Zai Lab Ltd - Median Os for Tivdak Not Reached VS Chemotherapy 10.7 Months

THOMSON REUTERS
·
15 Jan

BRIEF-Zai Lab, Vertex Sign Strategic Agreement To Develop, Commercialize Povetacicept In Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region And Singapore

Reuters
·
10 Jan

Zai Lab Ltd - to Handle Commercialization Activities for Povetacicept

THOMSON REUTERS
·
10 Jan

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

THOMSON REUTERS
·
10 Jan

Zai Lab Ltd - Vertex to Receive Upfront Payment, Milestone Payments, and Royalties

THOMSON REUTERS
·
10 Jan

Zai Lab Announces Strategic Partnership With Medilink Therapeutics to Develop a Novel Lrrc15 Antibody-Drug Conjugate

THOMSON REUTERS
·
10 Jan

Zai Lab Secures 300 Million Yuan Debt Facility

MT Newswires Live
·
06 Jan

BRIEF-Zai Lab Ltd Zai Lab Shanghai Entered Into Working Capital Loan Contract With Bocom Regarding Revolving Credit Facility Of Up To Rmb300 Million

Reuters
·
04 Jan

Zai Lab Ltd: Zai Lab Shanghai Entered Into Working Capital Loan Contract With BOCOM Regarding Revolving Credit Facility of up to RMB300 Mln

THOMSON REUTERS
·
04 Jan

Zai Lab and Novocure Announce Positive Topline Results From Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields (Ttfields) Therapy for Pancreatic Cancer

THOMSON REUTERS
·
02 Dec 2024

Zai Lab Announces the Inclusion of Augtyro® (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’s National Reimbursement Drug List

THOMSON REUTERS
·
28 Nov 2024

Zai Lab Raises $216 Million Through ADS Offering

MT Newswires Live
·
25 Nov 2024

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug Xacduro® (Sulbactam-Durlobactam)

THOMSON REUTERS
·
21 Nov 2024

Zai Lab Grants Share Units to Employees

MT Newswires Live
·
20 Nov 2024

BRIEF-Zai Lab Announces Public Offering Of 7.8 Million American Depositary Shares At A Price Of Us$25.50 Per ADS

Reuters
·
15 Nov 2024

Zai Lab Ltd - Public Offering of 7.8 Mln American Depositary Shares at a Price of US$25.50 per Ads

THOMSON REUTERS
·
15 Nov 2024

Zai Lab Proposes $200 Million Public Offering of American Depositary Shares

MT Newswires Live
·
14 Nov 2024